Halozyme Therapeutics, Inc. (HALO) compounding analysis
Full-size annual and quarterly year-over-year growth charts for revenue, EPS, operating cash flow, EBITDA, and free cash flow against the 15%, 20%, and 30% bars over 3-, 5-, and 10-year windows, with each metric's valuation multiple vs its own history.
Revenue · 10YDoes not currently clear the 15%+, 20%+, or 30%+ revenue bars over 10Y.
- Score
- 61/100
- 10Y CAGR
- 26.3%
- Median YoY
- 34.7%
- YoY volatility
- σ 45.0pp· choppy
- Quarters ≥ 20%
- 26 of 40
- Negative quarters
- 7
- Valuation vs own 10Y history
- Latest historical P/S 7.7x · 10Y median 9.8x · 30th percentile · as of Oct 6, 2026
How this score is computed
- Quarters at or above 20%: 26 of 40 → 26 of 40 pts
- Steadiness (typical swing 45.0pp) → 0 of 25 pts
- Pace (median 34.7% YoY) → 20 of 20 pts
- Latest quarter (47.7% YoY) → 15 of 15 pts
- Score: 61 of 100
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
Across metrics · 10Y
| Metric | 10Y CAGR | Median YoY | YoY σ | Qtrs ≥ 20% | Neg. qtrs |
|---|---|---|---|---|---|
| RevenueRevenue | 26.3% | 34.7% | 45.0pp | 26 of 40 | 7 |
| EPSEPS | — | — | — | — | — |
| Op cash flowOperating cash flow | — | — | — | — | — |
| EBITDAEBITDA | — | — | — | — | — |
| FCFFree cash flow | — | — | — | — | — |
Reported figures over 10Y: annual-series CAGR, median and standard deviation (σ, percentage points) of quarterly year-over-year growth, quarters at or above 20%, and quarters with negative YoY. “—” means the window needs more comparable data.
Scores, qualification bars, and the 0–100 consistency methodology are documented on the compounders list page →
See also: HALO on the compounders surface · All compounders, ranked